| MeSH term | MeSH ID | Detail |
|---|---|---|
| Myxoma | D009232 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Barth J and Hahne W | Review article: rabeprazole-based therapy in Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849125 |
| Tomioka H et al. | Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. | 2002 | Int. J. Antimicrob. Agents | pmid:11850167 |
| Sharara AI et al. | Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. | 2002 | Int. J. Antimicrob. Agents | pmid:11850169 |
| Krause M | [Resistance problems in gastrointestinal infections]. | 2002 | Ther Umsch | pmid:11851045 |
| Al-Eidan FA et al. | Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up. | 2002 | Br J Clin Pharmacol | pmid:11851640 |
| Sheu BS et al. | Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856088 |
| Choi IJ et al. | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856089 |
| Bazzoli F et al. | Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856090 |
| Rhomberg PR and Jones RN | In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. | 2002 | Diagn. Microbiol. Infect. Dis. | pmid:11858912 |
| Malfertheiner P et al. | Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860399 |
| Kim JS et al. | Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860410 |
| Poon SK et al. | Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860412 |
| Peitz U et al. | High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860415 |
| Masiá M et al. | Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. | 2002 | Arch. Intern. Med. | pmid:11863483 |
| Lim JA et al. | Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in a Korean hospital. | 2002 | J. Antimicrob. Chemother. | pmid:11864949 |
| Fujimura S et al. | In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. | 2002 | J. Antimicrob. Chemother. | pmid:11864956 |
| Levy M et al. | Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. | 2002 | Am. J. Gastroenterol. | pmid:11866264 |
| Christopher K et al. | Clarithromycin use preceding fulminant hepatic failure. | 2002 | Am. J. Gastroenterol. | pmid:11866297 |
| Narayani RI et al. | Resolution of collagenous colitis after treatment for Helicobacter pylori. | 2002 | Am. J. Gastroenterol. | pmid:11866305 |
| Malik R et al. | Feline leprosy: two different clinical syndromes. | 2002 | J. Feline Med. Surg. | pmid:11869054 |
| Shcherbakov PL | [Clarithromycin in eradication therapy of helicobacter infections in children]. | 2001 | Antibiot. Khimioter. | pmid:11871315 |
| Kumar D et al. | Pre and post eradication gastric inflammation in Helicobacter pylori-associated duodenal ulcer. | 2002 Jan-Feb | Indian J Gastroenterol | pmid:11871846 |
| Colebunders R and Florence E | Neuropsychiatric reaction induced by clarithromycin. | 2002 | Sex Transm Infect | pmid:11872875 |
| Khan J and Javed M | The incidence of non ulcer dyspepsia and its response to treatment. | 2001 Oct-Dec | J Ayub Med Coll Abbottabad | pmid:11873428 |
| Dabernat H et al. | [in vitro activity of telithromycin against Haemophilus influenzae]. | 2002 | Pathol. Biol. | pmid:11873632 |
| Di Caro S et al. | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876707 |
| Wu JC et al. | Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876709 |
| Mason J et al. | The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876711 |
| Georgopoulos SD et al. | Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876712 |
| Elizalde JI et al. | Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876713 |
| Okada S et al. | Angiocentric immunoproliferative lesions of the lung associated with diffuse renal involvement. | 2002 | Am. J. Kidney Dis. | pmid:11877592 |
| Melo-Cristino J et al. | [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000]. | Acta Med Port | pmid:11878155 | |
| Biechy M et al. | [Soft-tissue abscess caused by Rhodococcus equi in a patient on hemodialysis]. | 2001 | Nefrologia | pmid:11881436 |
| Ecclissato C et al. | Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. | 2002 | Helicobacter | pmid:11886474 |
| van Rooyen GF et al. | Sensitive liquid chromatography-tandem mass spectrometry method for the determination of clarithromycin in human plasma. | 2002 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:11890168 |
| Murata Y et al. | [Study on the detection methods of Helicobacter pylori from clinical specimens]. | 2002 | Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi | pmid:11895427 |
| Klein JL et al. | Prosthetic valve endocarditis caused by Bartonella quintana. | 2002 | Emerging Infect. Dis. | pmid:11897074 |
| Galarza M et al. | Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. | 2002 | Pediatr. Neurol. | pmid:11897483 |
| Ménard A et al. | PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:11897613 |
| Grove DI and Koutsouridis G | Increasing resistance of Helicobacter pylori to clarithromycin: is the horse bolting? | 2002 | Pathology | pmid:11902451 |
| Kornacker M et al. | Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases. | 2002 | Ann. Hematol. | pmid:11907791 |
| McNulty C et al. | Helicobacter pylori susceptibility testing by disc diffusion. | 2002 | J. Antimicrob. Chemother. | pmid:11909833 |
| Thiermann S et al. | Comparison of phenotypic and genotypic methods for the detection of clarithromycin resistance in Mycobacterium avium. | 2002 | J. Antimicrob. Chemother. | pmid:11909844 |
| Kalach N et al. | [Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children]. | 2002 | Arch Pediatr | pmid:11915493 |
| Kawakami E et al. | Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents. | 2001 Jul-Sep | Arq Gastroenterol | pmid:11917721 |
| Odaka T et al. | Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. | 2002 | Am. J. Gastroenterol. | pmid:11922552 |
| Ozawa S | [Drug-drug interaction in pharmacogenetics and pharmacogenomics]. | 2002 | Rinsho Byori | pmid:11925851 |
| Morimoto T et al. | [Cost-effectiveness analysis of ambulatory treatment for adult patients with community-acquired pneumonia: according to Japanese Respiratory Society guidelines]. | 2002 | Nihon Kokyuki Gakkai Zasshi | pmid:11925912 |
| Takemura Y et al. | [Mycobacterium abscessus infection complicated with diabetes mellitus]. | 2002 | Nihon Kokyuki Gakkai Zasshi | pmid:11925921 |
| Ciancio G et al. | Regression of duodenal gastric metaplasia in Helicobacter pylori positive patients with duodenal ulcer disease. | 2002 | Dig Liver Dis | pmid:11926569 |
| Borody TJ et al. | Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure? | 2002 | Dig Liver Dis | pmid:11926571 |
| Bazzoli F et al. | Treatment of Helicobacter pylori infection. Indications and regimens: an update. | 2002 | Dig Liver Dis | pmid:11926576 |
| Hermon-Taylor J | Treatment with drugs active against Mycobacterium avium subspecies paratuberculosis can heal Crohn's disease: more evidence for a neglected public health tragedy. | 2002 | Dig Liver Dis | pmid:11926580 |
| Sinisalo J et al. | Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. | 2002 | Circulation | pmid:11927522 |
| Pilotto A and Malfertheiner P | Review article: an approach to Helicobacter pylori infection in the elderly. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929385 |
| Wong WM et al. | One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929398 |
| Zheng X et al. | [The prevalence and mechanism of Helicobacter pylori resistance to clarithromycin in Beijing]. | 2001 | Zhonghua Yi Xue Za Zhi | pmid:11930609 |
| Shafran I et al. | Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. | 2002 | Dig Liver Dis | pmid:11930899 |
| Treadway G et al. | The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. | 2002 | Int. J. Antimicrob. Agents | pmid:11932140 |
| Böcher W et al. | [Skin nodules and ulcers of the limbs in a patient with rheumatoid arthritis]. | 2002 | Dtsch. Med. Wochenschr. | pmid:11935470 |
| Amsden GW et al. | A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. | 2002 | J Clin Pharmacol | pmid:11936570 |
| Ohlin B et al. | Dual versus triple therapy in eradication of Helicobacter pylori. | 2002 Jan-Feb | Hepatogastroenterology | pmid:11941946 |
| Kountouras J et al. | Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. | 2002 Jan-Feb | Hepatogastroenterology | pmid:11941952 |
| Hu YY et al. | Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000. | 2002 | Acta Paediatr. | pmid:11951998 |
| King A et al. | Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin. | 2002 | Clin. Microbiol. Infect. | pmid:11952721 |
| Olalla J et al. | Mycobacterium fortuitum complex endocarditis-case report and literature review. | 2002 | Clin. Microbiol. Infect. | pmid:11952729 |
| Baena JM et al. | Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. | 2002 | Eur J Gastroenterol Hepatol | pmid:11953695 |
| Tessier PR et al. | Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. | 2002 | Antimicrob. Agents Chemother. | pmid:11959578 |
| Lin CK et al. | One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. | 2002 May-Jun | J. Clin. Gastroenterol. | pmid:11960067 |
| Klotz U | Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. | 2002 | Arzneimittelforschung | pmid:11963641 |
| Uc A and Chong SK | Treatment of Helicobacter pylori gastritis improves dyspeptic symptoms in children. | 2002 | J. Pediatr. Gastroenterol. Nutr. | pmid:11964952 |
| Klok RM et al. | Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966514 |
| Tomita T et al. | Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966543 |
| Tsuzuki T et al. | Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966545 |
| Perri F et al. | Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. | 2002 | Helicobacter | pmid:11966868 |
| Nagayama M et al. | [Follicular bronchiolitis preceding rheumatoid arthritis]. | 2002 | Nihon Kokyuki Gakkai Zasshi | pmid:11974899 |
| Takashima J et al. | Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents. | 2002 | J. Nat. Prod. | pmid:11975515 |
| Chiba N et al. | Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. | 2002 | BMJ | pmid:11976244 |
| Giaconi J et al. | Bilateral Mycobacterium abscessus keratitis after laser in situ keratomileusis. | 2002 | J Cataract Refract Surg | pmid:11978473 |
| Paz A and Potasman I | Mycoplasma-associated carditis. Case reports and review. | 2002 | Cardiology | pmid:11978954 |
| Yamamoto N et al. | [Development of Helicobacter pylori eradication therapy]. | 2002 | Nippon Rinsho | pmid:11979775 |
| Imase K and Takahashi S | [Diagnosis of Helicobacter pylori infection by culture method]. | 2002 | Nippon Rinsho | pmid:11979798 |
| Murakami K and Nasu M | [Drug sensitivity test for Helicobacter pylori]. | 2002 | Nippon Rinsho | pmid:11979806 |
| Nakamura T | [The outline of medical treatment of peptic ulcer]. | 2002 | Nippon Rinsho | pmid:11979808 |
| Takeda H | [Current role of acid suppressants in the treatment of peptic ulcer disease]. | 2002 | Nippon Rinsho | pmid:11979809 |
| Kato M et al. | [Guidelines for the management of Helicobacter pylori infection in Japan]. | 2002 | Nippon Rinsho | pmid:11979813 |
| Kato S | [Guidelines of Helicobacter pylori eradication in children]. | 2002 | Nippon Rinsho | pmid:11979815 |
| Satoh K | [New triple therapy for Helicobacter pylori infection]. | 2002 | Nippon Rinsho | pmid:11979817 |
| Fu HY et al. | [Dual therapy for Helicobacter pylori resistance to anti microbial agents]. | 2002 | Nippon Rinsho | pmid:11979819 |
| Ohkusa T and Sato N | [Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection]. | 2002 | Nippon Rinsho | pmid:11979821 |
| Nagahara A et al. | [Effect of PPI/AM re-treatment regimen for the patients with Helicobacter pylori infection after failure of first line eradication therapy by PPI/AC regimens]. | 2002 | Nippon Rinsho | pmid:11979822 |
| Shirai N and Furuta T | [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism]. | 2002 | Nippon Rinsho | pmid:11979823 |
| Tokunaga K and Takahashi S | [Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection]. | 2002 | Nippon Rinsho | pmid:11979824 |
| Sato R et al. | [Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection]. | 2002 | Nippon Rinsho | pmid:11979825 |
| Mitsuno Y and Yoshida H | [Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication]. | 2002 | Nippon Rinsho | pmid:11979826 |
| Kagaya H et al. | [Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections]. | 2002 | Nippon Rinsho | pmid:11979827 |
| Inoue K and Sugano K | [Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection]. | 2002 | Nippon Rinsho | pmid:11979828 |
| Miwa H et al. | [Adverse effects of H. pylori eradication therapy and its measure]. | 2002 | Nippon Rinsho | pmid:11979829 |
| Sakaki N | [Acute mucosal lesion of the upper-gastrointestinal tract observed after H. pylori-eradication]. | 2002 | Nippon Rinsho | pmid:11979830 |
| Haruma K et al. | [H. pylori eradication therapy and natural history of peptic ulcer]. | 2002 | Nippon Rinsho | pmid:11979833 |